REG - Hemogenyx Pharma Plc - Result of AGM

Hemogenyx PharmaceuticalsAnnouncement

29/05/2025 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250529:nRSc6553Ka&default-theme=true

RNS Number : 6553K  Hemogenyx Pharmaceuticals PLC  29 May 2025

29 May 2025

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual
General Meeting ("AGM") held earlier today, all resolutions were duly passed
by shareholders. The numbers of proxy votes for each resolution submitted
prior to the meeting are presented below.

 

Proxy Voting Results

 Ordinary Resolutions                                                            Votes for  % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)   Votes with-held (2)
 1. To receive and adopt the Company's annual accounts for the financial year    769,396    97.31                21,278         2.69                     790,674           18.20                              12,514
 ended 31 December 2024 together with the directors' reports and auditor's
 report on those accounts
 2. To approve the Directors' Remuneration Report                                621,455    78.62                168,962        21.38                    790,417           18.20                              12,771
 3. To authorise the re-appointment of Peter Redmond                             601,846    75.44                195,969        24.56                    797,815           18.37                              5,373
 4. To re-appoint PKF Littlejohn LLP as auditors                                 729,108    95.29                36,001         4.71                     765,109           17.61                              38,079
 5. To authorise the Audit Committee to determine the level of the auditor's     647,389    85.67                108,250        14.33                    755,639           17.40                              47,549
 remuneration
 6. To grant the Directors authority to allot and issue shares and grant rights  639,852    81.03                149,808        18.97                    789,660           18.18                              13,528
 to subscribe for shares in the Company for the purposes of Section 551 of the
 Act.
 Special Resolutions                                                             Votes for  % of votes cast for  Votes against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)   Votes with-held (2)
 7. To dis-apply the statutory rights of pre-emption in respect of the           638,646    80.88                151,014        19.12                    789,660           18.18                              13,528
 allotment of equity securities for cash under Section 561(1) of the Act.
 8. To authorise the Directors to call a general meeting of the Company, other   763,850    96.72                25,924         3.28                     789,774           18.18                              13,414
 than an annual general meeting,

 

(1)        The Company's issued share capital ("ISC") on 27 May 2025,
being the date on which members had to be entered in the register of members
of the Company in order to be entitled to attend and vote at the meeting, was
4,343,539 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a
vote in law and is not counted in the calculation of the proportion of the
votes for and against it.

 

A copy of the resolutions passed has been submitted to the National Storage
Mechanism and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSELFDUEISESI